EUVIMEDEUVIMED entdecken
Crossref

Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K

Rong Wang, Shutao Jia, Hongyan Chen, Kaitao Luo, Limei Zhang, Yan Song, Chen Qing, Dandan Liu, Hongyu Zhou

Biochemical Pharmacology · 2024

DOI: 10.1016/j.bcp.2024.116408 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biochemical Pharmacology, 2024. Verfasst von Rong Wang und 8 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmaceutical Science & Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming 650500, Yunnan, Ch…. Hauptthemen laut MEDLINE: Ticagrelor, Triple Negative Breast Neoplasms, Mice, Inbred BALB C. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 48 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Metastatic recurrence is still a major challenge in breast cancer treatment. Patients with triple negative breast cancer (TNBC) develop early recurrence and relapse more frequently. Due to the lack of specific therapeutic targets, new targeted therapies for TNBC are urgently needed. Phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt)/mammalian target of rapamycin (mTOR) pathway is one of the active pathways involved in chemoresistance and survival of TNBC, being considered as a potential target for TNBC treatment. Our present study identified ticagrelor, an anti-platelet drug, as a pan-PI3K inhibitor with potent inhibitory activity against four isoforms of class I PI3K. At doses normally used in clinic, ticagrelor showed weak cytotoxicity against a panel of breast cancer cells, but significantly inhibited the migration, invasion and the actin cytoskeleton organization of human TNBC MDA-MB-231 and SUM-159PT cells. Mechanistically, ticagrelor effectively inhibited PI3K downstream mTOR complex 1 (mTORC1) and mTORC2 signaling by targeting PI3K and decreased the protein expression of epithelial-mesenchymal transition (EMT) markers. In vivo, ticagrelor significantly suppressed tumor cells lung metastasis in 4T1 tumor bearing BALB/c mice model and experimental lung metastasis model which was established by tail vein injection of GFP-labeled MDA-MB-231 cells. The above data demonstrated that ticagrelor can inhibit the migration and invasion of TNBC both in vitro and in vivo by targeting PI3K, suggesting that ticagrelor, a pan-PI3K inhibitor, might represent a promising therapeutic agent for the treatment of metastatic TNBC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TicagrelorTriple Negative Breast NeoplasmsMice, Inbred BALB CAnimalsHumansFemaleMiceCell Line, TumorPlatelet Aggregation InhibitorsMice, NudePhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase InhibitorsXenograft Model Antitumor AssaysCell MovementNeoplasm Metastasis

Stichwörter der Autor:innen

Epithelial-mesenchymal transition (EMT)MetastasisPhosphoinositide 3-kinase (PI3K)TicagrelorTriple-negative breast cancer (TNBC)

Substanzen

TicagrelorPlatelet Aggregation InhibitorsPhosphatidylinositol 3-KinasesPhosphoinositide-3 Kinase Inhibitors

Autor:innen und Institutionen

  • School of Pharmaceutical Science & Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming 650500, Yunnan, China.
  • School of Pharmaceutical Science & Yunnan Key Laboratory of Pharmacology for Natural Products, Kunming Medical University, Kunming 650500, Yunnan, China; Yunnan College of Modern Biomedical Industry, Kunming Medical Uni…

Zitieren

APA

Wang, R., Jia, S., Chen, H., Luo, K., Zhang, L., Song, Y., Qing, C., Liu, D., & Zhou, H. (2024). Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K. Biochemical Pharmacology. https://doi.org/10.1016/j.bcp.2024.116408

Vancouver

Wang R, Jia S, Chen H, Luo K, Zhang L, Song Y, et al. Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K. Biochemical Pharmacology. 2024. doi:10.1016/j.bcp.2024.116408

BibTeX
@article{Wang2024,
  author = {Wang, Rong and Jia, Shutao and Chen, Hongyan and Luo, Kaitao and Zhang, Limei and Song, Yan and Qing, Chen and Liu, Dandan and Zhou, Hongyu},
  title = {Antiplatelet drug ticagrelor suppresses triple negative breast cancer metastasis by targeting PI3K},
  journal = {Biochemical Pharmacology},
  year = {2024},
  doi = {10.1016/j.bcp.2024.116408}
}
Kostenlos starten →